Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151398 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
NCT00151398 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 229 participants.
The verdict
NCT00151398, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
Study Summary
The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
Interventions
- DRUG Donepezil
- DRUG lecozotan SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2005-10-06 |
| Est. Completion | 2008-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151398
The ClinicalTrials.gov registry entry for NCT00151398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donepezil is the first listed.
NCT00151398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151398 about?
NCT00151398 is a clinical study titled "Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)". The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.
What is the current status of trial NCT00151398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2005-10-06. Estimated completion is 2008-03-15.
What interventions are being tested in trial NCT00151398?
The interventions under investigation include: Donepezil (DRUG), lecozotan SR (DRUG).
Who is sponsoring clinical trial NCT00151398?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.